S l e e p D i s o rde r s i n Pregnancy Dennis Oyiengo, MDa, Mariam Louis, MDb, Beth Hottc, Ghada Bourjeily, MDd,* KEYWORDS Pregnancy Restless legs syndrome Narcolepsy Insomnia Circadian rhythm Sleep-disordered breathing
KEY POINTS Pregnancy is associated with physiologic changes that may disrupt sleep, cause sleep disorders, or worsen underlying sleep conditions. Restless legs syndrome may occur de novo in pregnancy or could potentially be exacerbated by increased iron or folate requirements. Sleep-disordered breathing may be exacerbated or caused by pregnancy; the disorder is associated with adverse pregnancy outcomes.
causing sleep fragmentation in late pregnancy. Nocturia is a common occurrence in the first and third trimesters. Nocturia is related to an increase in the overnight sodium secretion, leading to a higher overnight urine flow. In late pregnancy, nocturia is worsened by the effect of the growing uterus on bladder capacity.4 Fetal movements can disrupt sleep, and musculoskeletal discomfort related to musculoskeletal changes of pregnancy also can result in sleep fragmentation. In the postpartum period, sleep is naturally disrupted and restricted by the needs of the newborn. Some pathologic respiratory conditions, such as asthma, may be exacerbated by physiologic changes of pregnancy, such as nasal congestion, heartburn, and immune changes, resulting in disrupted sleep. Management of the various conditions in the pregnant population is complicated by concern for fetal well-being and the impact of treatment on the safety of the unborn child. Nonetheless, management decisions should also take into
a Pulmonary and Critical Care Fellowship Program, The Warren Alpert Medical School of Brown University, 593 Eddy Street, Providence, RI 02903, USA; b Department of Medicine, University of Florida, 655 West 8th Street, Jacksonville, FL 32209, USA; c Department of Medicine, Women’s Medicine Collaborative, The Miriam Hospital, 146 West River Street, Suite 11C, Providence, RI 02904, USA; d Department of Medicine, The Miriam Hospital, The Warren Alpert Medical School of Brown University, 146 West River Street, Suite 11C, Providence, RI 02904, USA * Corresponding author. The Miriam Hospital, 146 West River Street, Suite 11C, Providence, RI 02904. E-mail address: [email protected]
Clin Chest Med - (2014) -–http://dx.doi.org/10.1016/j.ccm.2014.06.012 0272-5231/14/$ – see front matter Ó 2014 Elsevier Inc. All rights reserved.
chestmed.theclinics.com
Sleep disturbances in pregnancy have been well recognized since Hippocrates. In 2000, the American Academy of Sleep Medicine officially recognized sleep disorders associated with pregnancy as a separate entity defined as the occurrence of insomnia or excessive daytime sleepiness in the course of pregnancy.1 The past decade has witnessed the emergence of numerous publications on various sleep disorders associated with pregnancy. Pregnancy is a unique, short-lived state that is associated with profound physiologic changes that may predispose individuals to the development of sleep disturbances; these changes also may exacerbate preexisting conditions. Many pregnancy-related factors may result in sleep disruption.2 Heartburn is significantly more common in pregnancy and has been reported in up to 75% of pregnancies in one study.3 Oxytocin, the hormone that is responsible for uterine contractions, is known to peak at night, possibly
2
Oyiengo et al consideration the effect of the untreated conditions on the health of the pregnancy and the fetus. This review focuses on nonbreathing-related sleep disorders, with a brief mention of sleep-disordered breathing. A detailed discussion of physiologic changes of pregnancy resulting in sleep disruption is outside the scope of this article.
In summary, sleep-disordered breathing is prevalent in pregnancy and is associated with adverse outcomes. Optimal management of pregnant women with obstructive sleep apnea is unclear and should follow nonpregnant guidelines until evidence suggesting that CPAP modifies pregnancyspecific outcomes exists.
SLEEP-DISORDERED BREATHING
RESTLESS LEGS SYNDROME
Many of the physiologic changes of pregnancy predispose to sleep-disordered breathing. Upper airway edema,5 increased Mallampati score,6 nasal congestion,7 and reduction in functional residual capacity8 are all predisposing factors, as they contribute to decreased airway patency and increased collapsibility. Despite protective factors, the balance tips toward a higher incidence of sleep-disordered breathing in this population compared with the nonpregnant population. Sleep-disordered breathing has been repeatedly associated with negative pregnancy outcomes, such as gestational hypertensive disorders,9,10 gestational diabetes,9,11–14 and cesarean deliveries.9,10 Adverse fetal outcomes also have been described, but are less consistent. Growth restriction has been described in some studies,15,16 but not others.9,17–20 Preterm birth has been described in women who snore or have obstructive sleep apnea,9,10 but this complication is likely mediated by preeclampsia. Fetal heart rate decelerations were described in clinical studies21,22; however, recent polysomnographic data do not show decelerations following apneic episodes.23 One recent retrospective study has shown that the risk of a composite set of adverse outcomes increases with the severity of sleep-disordered breathing.24 These data suggest that, like the nonpregnant population, pregnant women with more severe disease need to be offered treatment. It remains unclear, however, whether continuous positive airway pressure (CPAP) alters pregnancy outcomes. Small studies and case series of women with obstructive sleep apnea25,26 show an improvement in daytime somnolence, quality of life, and other symptoms, such as morning headaches. However, the impact of CPAP on the prevention of gestational hypertension, gestational diabetes, or fetal outcomes in the setting of obstructive sleep apnea remains unclear. Minimal data have assessed sleep-disordered breathing outside the setting of obstructive sleep apnea and snoring. Central sleep apnea appears to be quite uncommon in pregnant women with sleep-disordered breathing.27 Treatment of these conditions is usually extrapolated from the nonpregnant population.
Restless legs syndrome (RLS), now known as Willis Ekbom disease (WED), is a sensorimotor phenomenon characterized by an urge to move the legs because of an unpleasant sensation; the urge is worse during periods of rest or inactivity and is partially or totally relieved by movement, and the sensation is worse during the evening or at night. Although a sleep study is not required to make the diagnosis of RLS/WED, the vast majority of patients with RLS/WED have evidence of periodic limb movements and arousals on polysomnography.28 Depending on methodology in communitybased surveys in the nonpregnant population, RLS/WED estimates fall between 1.9% and 15.0%29 and appear to have a female predominance.30 RLS/WED has a higher prevalence in pregnancy, with more than a quarter of pregnant women reported to have the syndrome in some studies.31,32 However, the methodology and the gestational age at the time of administration of questionnaires in these epidemiologic studies varied significantly. Although some used selfadministered questionnaires,33,34 others used interview-based information.35–37 Timing of data collection also varied significantly, with some studies performing the assessment longitudinally throughout pregnancy,38,39 while others performed a cross-sectional analysis at various points during pregnancy.31,40 Importantly, the number of criteria met for the diagnosis of RLS also differed between studies. In a study that performed face-to-face interviews with pregnant women conducted at delivery, nearly a quarter of pregnant women met criteria for RLS according to the International Restless Legs Syndrome Study Group criteria.35 Almost two-thirds of these women had newonset symptoms, whereas about one-third had symptoms predating pregnancy. The prevalence of RLS appears to increase with gestational age,33,38,39 suggesting de novo symptoms. For most women, symptoms resolve shortly after delivery.36,40 Lower prevalence was reported in other studies33 and the discrepancy may be related to methodology and the diagnostic criteria used.
Sleep Disorders in Pregnancy Pathophysiology RLS has been linked to dopamine metabolism in the brain, and it is thought that the disorder arises from dysfunction of hypothalamic dopaminergic cells that are the source of spinal dopamine. By impeding the production of tyrosine hydroxylase in the central nervous system, reduced serum iron hinders the production of dopamine. A potential mechanism for the higher prevalence of RLS in pregnancy may be the threefold to fourfold increase in iron requirements in pregnancy.32 As the mother is the sole source of nutrients to the fetus, the placenta upregulates its iron transfer systems to maintain adequate supply to the fetus, which often occurs at the expense of the mother’s stores.41 This upregulation is more pronounced under conditions of maternal iron deficiency.42 As many as 30% of women have limited iron stores in wealthy cities in developed countries43 and up to 90% of pregnant American women have suboptimal iron intake.44 Serum iron follows a circadian pattern and levels are 50% to 60% lower at night than in the daytime, and nadir levels appear to correlate with the highest severity of symptoms. Although serum iron and iron saturation are decreased in 62% and 77% of patients with RLS, respectively, serum ferritin levels and markers of anemia based on hemoglobin and red blood cell mass were decreased in fewer than a quarter of patients in one study.45 Ferritin levels less than 50 ng/ mL correlate well with poor sleep quality and higher symptom severity scores.46 As attractive as this theory of iron deficiency is in explaining the higher prevalence of RLS in pregnancy, it does not explain the rapid improvement that occurs postpartum, as blood loss at delivery and fluid shifts postpartum would likely worsen anemia. Furthermore, folate deficiency also may play a role in the pathogenesis of RLS in pregnancy. Folate requirements increase 8-fold to 10-fold in pregnancy because of the increased demands of the fetus. The incidence of RLS is significantly lower in women who use vitamin supplementation throughout pregnancy compared with those who do not,37,47 and resolution of symptoms correlates with normalization of levels.48 Female hormones may be culprits as well. Through interactions with the dopaminergic system, namely the nigrostriatal dopaminergic neurons, estradiol may play a role in RLS.49 In a small study of 10 pregnant women with RLS and pregnant controls without RLS, estradiol levels were significantly higher in women with RLS, irrespective of whether RLS predated the pregnancy or occurred de novo in pregnancy.50 A more recent study that excluded pregnant women being
treated with intravenous iron for iron deficiency, reported a lower prevalence of the disorder than previously described (12%) and showed similar levels of third-trimester estradiol levels in pregnant women with RLS compared with controls.51 Prolactin also influences the dopaminergic system, has the same circadian rhythmicity as RLS, and may play a role in RLS in pregnancy. However, the drastic improvement in symptoms in the postpartum period, even in lactating women,52 argues against a prominent role of this hormone. Progesterone increases several-fold in pregnancy. Although progesterone increases neuronal excitability and may theoretically manifest this excitability as RLS, progesterone levels in pregnant women with RLS were not found to be higher than those without the syndrome.37,50
Management Certain conditions should be excluded before diagnosing a patient with RLS, such as electrolyte imbalance and peripheral vasculopathy, but some conditions need to be specifically considered in the pregnant population. Leg cramps are quite common in pregnancy and may mimic RLS symptoms. Musculoskeletal discomfort is common, and nerve impingement should be considered, especially if symptoms are unilateral. RLS has been linked to hypertension in some general population studies,53,54 but only one recent study has evaluated a link between RLS and pregnancy outcomes.55 Until this association is confirmed in additional studies, it is premature to think that treatment of RLS could modify any pregnancy outcomes. Similar to nonpregnant patients, known triggers to RLS, such as caffeine, smoking, and certain drugs, should be eliminated if possible. RLS has been described in association with the use of some antidepressants in some studies56–58 but not in others.59,60 As untreated mood disorders are associated with adverse pregnancy outcomes, the safety of withholding or switching antidepressants should be carefully assessed, preferably by a perinatal psychiatrist, and the risk and benefit of such a decision carefully weighed. In 2012, American Academy of Sleep Medicine practice parameters summarized available options for the treatment of RLS in the general population and in some special populations, but provided no recommendations for the pregnant population.61 Although moderate and high-quality evidence supports the use of some drugs in the treatment of RLS, first-line therapy varies in pregnancy because of the scarcity of safety data in this population. Table 1 summarizes the safety
3
4
Table 1 Pharmacotherapy and drug safety in restless legs syndrome
Pramipexole (Approved for indication)
Ropinirole (Approved for indication)
Levodopa (Approved, but off-label use)
Opioids (Approved, but off-label use)
Gabapentin (Approved for indication)
Carbamazepine (Approved, but off-label use)
Pregnancy Safety
Lactation
Based on studies in rats and rabbits, an increase in malformations is not anticipated in women treated with pramipexole during pregnancy.62 Human safety data are limited to case reports and case series but do not show evidence of malformations. There are no human data. Based on experimental animal studies, ropinirole is not expected to increase the risk of congenital anomalies. One case report has been identified on use of Ropinirole in pregnancy.135 Levodopa produces adverse pregnancy and fetal outcomes136–138 in experimental animals after high-dose treatment. Case reports in humans have not identified abnormal embryo or fetal development. Theoretic concern about placental perfusion with levodopa.139 Current data do not support the safety of this drug in pregnancy. Neonatal withdrawal after maternal use has occurred with opioid medications. Oxycodone use in the first trimester was associated with an increase in pulmonary valve stenosis in one retrospective study.140 Study limited by maternal recall and findings confounded by indication for use. These findings were not confirmed in other studies.141–143 Gabapentin has been reported to interfere with embryo development in some but not all experimental studies. There are case reports of normal pregnancy outcomes after gabapentin therapy, but there are also reports of malformations. It is not known if the risk of malformations in increased with this medication. Carbamazepine use during early pregnancy has been associated with an increased risk of neural tube defects and possibly an increased risk of craniofacial abnormalities and developmental delay. In spite of these risks, this drug has been used for optimal seizure control as benefit likely outweighs the risk in most cases. However, until RLS is clearly linked to adverse pregnancy outcomes, the use of carbamazepine for the treatment of RLS may not outweigh the risk of fetal malformations.
No human studies assessing levels in breast milk are available. Pramipexole is known to reduce the secretion of prolactin, and it is possible that it could significantly reduce milk synthesis in breastfeeding mothers. This product should probably not be used in breastfeeding mothers.63 No human studies are available concerning levels in milk. Medication might inhibit lactation because of its prolactinlowering effects. This product should probably not be used in breastfeeding mothers.63 No pediatric concerns reported. However, reduced prolactin levels by dopamine may reduce milk production.63
Small amounts are secreted in breast milk. Sedation of the newborn may be observed.63
Data reveal that the infant plasma levels following exposure to gabapentin through breastfeeding are probably too low to cause untoward effects in the breastfed infant. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding. The amount of carbamazepine transferred to the infant is apparently quite low. Medication usually compatible with breastfeeding according to the American Academy of Pediatrics (AAP) and World Health Organization (WHO).
Oyiengo et al
Medications Restless Leg Syndrome (RLS)
Clonidine (Approved, but off-label use)
Pregabalin (Approved, but off-label use)
Rotigotine (Withdrawn from US market because of drug crystallization affecting absorption) Bromocriptine
Cabergoline
Clonazepam
Magnitude of potential teratogenic effect is undetermined. No animal teratology studies have been published.
Based on experimental animal studies and limited human experience, bromocriptine use during pregnancy is not believed to increase the risk of congenital anomalies. Risk and benefit of the use of this drug should be carefully weighed in women with RLS. Human studies of more than 500 pregnancies exposed to cabergoline suggest that the drug does not increase the risk of congenital malformations. Cabergoline has been used to increase fertility in women with prolactinomas. Maternal use of valproic acid alone or in combination with other antiepileptic drugs has been found to cause valproic acid syndrome in infants. Facial dysmorphology, congenital heart defects, spina bifida, cleft lip and palate, and developmental delays are some of the teratogenic effects seen. The use of this drug for the treatment of RLS in pregnancy cannot be justified. Maternal use is not thought to increase the risk of congenital malformations. Risk of transient respiratory distress and hypotonia in women taking clonazepam in combination with paroxetine.
Clonidine is minimally excreted in human milk. No pediatric concerns reported, but newborns may need to be observed for hypotension. Clonidine may reduce milk production by reducing prolactin secretion.
There are no data available on the transfer of pregabalin into human milk. However, due to the kinetics of the drug, its passage into the milk compartment is probable, and its oral bioavailability to the infant would be high. Therefore, infant risk cannot be ruled out. No data are available on the transfer of rotigotine into human milk. It is possible that this medication could significantly decrease prolactin release and in turn, decrease milk production. No reports of direct toxicity to infant via milk, but use with caution. May inhibit lactation.
Drug used to treat prolactinomas and is known to decrease prolactin levels. If lactation can be maintained, watch infant for ergot effects, if any. No adverse events have been associated with breastfeeding. Maternal medication usually compatible with breastfeeding according to the AAP and WHO. Monitor infant for side effects.
One case report of apnea, cyanosis, and hypotonia in a newborn exposed to clonazepam via breast milk.145 Other reports (11 newborns) showed no side effects.146
Sleep Disorders in Pregnancy
Valproic acid
Based on experimental animal studies, clonidine use during pregnancy is not expected to increase the risk of structural malformations. Possible behavioral effects, such as hyperactivity and sleep disturbances, were reported in children exposed prenatally compared with a control population.144 Similar behavioral effects of prenatal clonidine exposure have been reported in experimental animals. Pregabalin has adverse effects on embryo development and viability in rats at plasma levels about twice those achieved in humans on therapy. Human data are limited.
5
6
Oyiengo et al data available both in pregnancy and lactation. Reprotox.org and Thomas Hale’s Medications and Mothers’ Milk62,63 are excellent sources of updated information on drug safety during pregnancy and lactation. Briefly, iron supplementation starting at ferritin less than 50 ng/mL or hemoglobin less than 11 g/dL may result in symptomatic improvement in women with low iron stores or iron deficiency. Preliminary data describing the use of intravenous iron supplementation appear to be promising. Data published in an abstract form on 11 women with moderate to severe iron deficiency–associated RLS and treated with intravenous iron in the third trimester showed a significant improvement in RLS severity score from 25 5 to 7 6, P 5 .01, 4 weeks after administration.64 The effect of the mild reduction in blood pressure associated with iron infusion on placental perfusion remains unclear and more data are needed to assess the exact role of this therapy in pregnancy. Although case reports of intravenous magnesium were associated with significant improvement in RLS symptom score, the Food and Drug Administration recently issued a warning against the use of intravenous magnesium for more than 5 to 7 days because of the effect of this mineral on calcium metabolism and fetal bone development. In addition to oral or intravenous iron supplementation in women with iron deficiency, clonidine, opioids, and clonazepam are potential therapeutic options in pregnancy, although none is standard therapy based on the recent practice parameters classification.61 Newborns exposed to opioids in utero should be observed closely for respiratory depression, or the drugs discontinued close to term. Although bromocriptine and cabergoline have been used to improve fertility and in pregnancy in women with prolactinomas, the risk-benefit ratio of the use of these drugs in RLS in pregnancy is less clear. In our opinion, these medications should be reserved for more severe cases in which symptoms are significantly disrupting sleep and are not responding to other therapy. In summary, RLS/WED is a common disorder in pregnancy that adversely affects sleep. Iron, folate, and hormones may each play a role in the pathogenesis of this disorder; however, the exact mechanism underlying this higher prevalence is unclear. Drugs with lower quality of evidence in the nonpregnant population than first-line therapy may be options for therapy in pregnancy.
INSOMNIA The National Sleep Foundation recommends 7 to 9 hours of sleep per 24 hours for adults65; however,
sleep needs and duration vary by age and gender and are likely different in pregnancy. Although selfreported sleep duration does not correlate well with subjective measurements, such as actigraphy, in pregnancy,66,67 most epidemiologic studies evaluating sleep duration rely on self-reports.68,69 Based on these studies, it appears that sleep duration increases starting in the first trimester and is then reduced late in pregnancy.70–72 These reports suggest that sleep needs are likely increased in pregnancy, or that longer sleep duration is related to rising levels of hormones necessary for maintaining pregnancy, such as human chorionic gonadotropin and progesterone.2 However, the emerging literature suggesting an association of sleep deficiency with some adverse outcomes in pregnancy may indicate that the longer sleep duration may be a necessary phenomenon rather than a mere side effect of hormonal changes. Sleep disruption is a common occurrence in pregnancy, and in many cases, sleep fragmentation may be related to physiologic changes of pregnancy. Many factors, such as musculoskeletal discomfort, heartburn, nocturia, uterine contractions, and fetal movement, may all disrupt sleep.2,73 Disrupted sleep is more prevalent in the third trimester and more than half of women report poor sleep in the last 8 weeks of gestation.74 As a result of fragmented nocturnal sleep, daytime napping increases in late pregnancy. Factors that have been associated with shorter sleep duration75 and worse insomnia severity scores in pregnancy76 include nulliparity, younger age,75 smoking, advanced gestational age, and higher blood pressure.76 Postpartum sleep is usually disrupted by the newborn’s nocturnal needs and potential postpartum discomfort, with more frequent complaints of insomnia in women with operative deliveries.77 Higher Epworth Sleepiness Scale (ESS) scores also have been described in pregnancy, with up to 24% of women reporting excessive sleepiness.76,78,79 Although daytime sleepiness may relate to physiologic sleep disruption, ESS scores appear to correlate with sleep-disordered breathing80 and may add to the risk of some adverse pregnancy outcomes related to snoring.8
Sleep Deficiency and Pregnancy Outcomes Although poor sleep in the antepartum period is related to normal physiologic changes of pregnancy in many, differentiating between normal and abnormal sleep in pregnancy may be challenging but an important task nonetheless, as poor sleep has been linked to adverse pregnancy outcomes. Sleep disruption or deficiency during
Sleep Disorders in Pregnancy pregnancy is considered a significant risk factor for the occurrence of mood disturbances,81–85 as well as the recurrence of depression.86 More so, a recent placebo-controlled randomized clinical trial with diphenhydramine, trazodone, or placebo has shown a significant improvement in the sleep profile of women treated with any of the active drugs during pregnancy compared with placebo, and a significant reduction in depressive symptoms 2 and 6 weeks after delivery.87 Another pilot open intervention tested the effect of cognitive behavioral therapy for insomnia on mood, sleep, and fatigue in women with depression and insomnia.88 This study has shown significant improvement in sleep efficiency and total wake time on sleep diary, in addition to significant enhancement of subjective mood and insomnia severity, sleep quality, and fatigue. These studies do suggest that there may be a causal link between sleep duration and quality and insomnia in peripartum women. Other outcomes that have been linked to short sleep duration include labor duration and delivery mode. In a study by Lee and Gay,89 the investigators showed that short sleep duration (less than 6 hours) in the last month of pregnancy was associated with longer labor duration and a higher risk of cesarean deliveries in nulliparous women. Similar studies have demonstrated the association of nocturnal and diurnal total sleep time with these outcomes.75,90,91 It is possible that abnormal sleep may lead to fatigue, which may then predispose to longer labor. However, factors that may lead to both poor sleep and longer labor, such as emotional stressors, also may explain these findings but have not yet been elucidated. Preterm birth, defined as birth occurring before 37 completed weeks of gestation, is a major health burden and a source of significant infant morbidity. Studies from more than 2 decades ago suggested a connection between sleep disruption and preterm labor. Nearly half of women residents who spent at least 1 night a week without any sleep or worked long hours were more likely to experience preterm labor than male residents’ partners.92,93 More recently, poor sleep quality measured by the Pittsburgh Sleep Quality Index (PSQI) was shown to be associated with preterm birth.94 Despite of these findings, little has been done to investigate the link between sleep deprivation and preterm labor. It is possible that inflammation and hypothalamic pituitary axis (HPA) dysfunction, which are believed to be potential underlying mechanisms for preterm labor, are negatively influenced by poor sleep. Sleep disturbances measured by the PSQI and sleep diaries were shown to be associated with increased levels
of interleukin 695 and C-reactive protein96 in pregnancy. As sleep, mood disturbances, and stress may be associated with HPA dysfunction, which has been linked to preterm birth, preliminary data are evaluating the interactions among these disturbances.97
Treatment Cognitive behavioral therapy (CBT) is recommended for the treatment of insomnia in the nonpregnant population. Data on the use of CBT in pregnancy are lacking. One recent study has reported an improvement in sleep measures and mood in women with insomnia and depression who were treated with CBT for insomnia.88 Because of fears of teratogenicity, many drugs are avoided in pregnancy. A recent study98 showed no increase in the risk of congenital anomalies in women treated with nonbenzodiazepines zaleplon (n 5 32), zolpidem (n 5 603), and zopiclone (n 5 692). Table 2 summarizes the safety data of drugs commonly used for the treatment of insomnia. In summary, sleep disruption is common in pregnancy and may be due to physiologic factors. As poor sleep has been associated with adverse pregnancy outcomes, testing whether interventions to improve sleep quality would have a positive effect on pregnancy outcomes is needed.
NARCOLEPSY Narcolepsy is an uncommon clinical syndrome of daytime sleepiness and may be accompanied by cataplexy, hypnagogic hallucinations, and sleep paralysis. Narcolepsy can occur with or without cataplexy. According to the US population estimates, it afflicts approximately 1 in 3000 individuals.99 As narcolepsy peaks in the adolescent years to early 20s, it is likely that women who carry the diagnosis will have a pregnancy complicated by the disorder.
Pathophysiology The symptoms of narcolepsy largely reflect a dysregulation of the transition between wakefulness, non–rapid eye movement (REM), and REM sleep.100–102 The normal sleep-wake cycle is regulated by a complex interaction of neurohormones and chemicals. Hypocretin 1 and 2 (Orexin A and B) are neuropeptides synthesized in the lateral hypothalamus and are implicated in the pathogenesis of narcolepsy.103,104 Hypocretins/orexins, peptides produced by the lateral hypothalamus, orchestrate the interaction of the monoaminergic and cholinergic systems in the regulation of sleep
7
8
Pregnancy Safety
Lactation
Zaleplon
Study of 32 pregnant women suggests no increased risk of teratogenicity; however, numbers too small to be conclusive.98
Zolpidem
Study of 603 pregnancies with zolpidem exposure showed no increased risk of congenital anomalies.98 However, population-based study in Taiwan (n 5 2497 exposed women and 12,485 unexposed) showed an increased risk of low birth weight and preterm deliveries in women but no increased risk of congenital anomalies.148 Study of 692 pregnancies showed no increased risk of malformations.98 Other smaller studies showed similar results.151,152 Crosses placental barrier and withdrawal reported at birth.153 Animal studies suggest dose-dependent incidence of diaphragmatic hernia and scapular shape abnormalities.154 Human data are lacking. Large-scale studies and case-control data fail to show an association with congenital malformations.155,156 Not likely to result in major congenital malformations based on human reports.157–159 Based on animal and human reports, the drug is not expected to increase the risk of congenital malformations but human reports are scarce. Based on animal and human studies, the drug is not expected to increase the risk of congenital malformations.162 There is some suggestion in the literature that first-trimester use may be associated with various (rather than a single) anomalies.163,164 Early data on diazepam and chlordiazepoxide use in first trimester suggesting increased risk of cleft palate were not supported by later studies. Concern about neonatal withdrawal with late third-trimester use. Concomitant use with diphenhydramine has been associated with fetal death.165
Estimated infant dose
KEY POINTS Pregnancy is associated with physiologic changes that may disrupt sleep, cause sleep disorders, or worsen underlying sleep conditions. Restless legs syndrome may occur de novo in pregnancy or could potentially be exacerbated by increased iron or folate requirements. Sleep-disordered breathing may be exacerbated or caused by pregnancy; the disorder is associated with adverse pregnancy outcomes.
causing sleep fragmentation in late pregnancy. Nocturia is a common occurrence in the first and third trimesters. Nocturia is related to an increase in the overnight sodium secretion, leading to a higher overnight urine flow. In late pregnancy, nocturia is worsened by the effect of the growing uterus on bladder capacity.4 Fetal movements can disrupt sleep, and musculoskeletal discomfort related to musculoskeletal changes of pregnancy also can result in sleep fragmentation. In the postpartum period, sleep is naturally disrupted and restricted by the needs of the newborn. Some pathologic respiratory conditions, such as asthma, may be exacerbated by physiologic changes of pregnancy, such as nasal congestion, heartburn, and immune changes, resulting in disrupted sleep. Management of the various conditions in the pregnant population is complicated by concern for fetal well-being and the impact of treatment on the safety of the unborn child. Nonetheless, management decisions should also take into
a Pulmonary and Critical Care Fellowship Program, The Warren Alpert Medical School of Brown University, 593 Eddy Street, Providence, RI 02903, USA; b Department of Medicine, University of Florida, 655 West 8th Street, Jacksonville, FL 32209, USA; c Department of Medicine, Women’s Medicine Collaborative, The Miriam Hospital, 146 West River Street, Suite 11C, Providence, RI 02904, USA; d Department of Medicine, The Miriam Hospital, The Warren Alpert Medical School of Brown University, 146 West River Street, Suite 11C, Providence, RI 02904, USA * Corresponding author. The Miriam Hospital, 146 West River Street, Suite 11C, Providence, RI 02904. E-mail address: [email protected]
Clin Chest Med - (2014) -–http://dx.doi.org/10.1016/j.ccm.2014.06.012 0272-5231/14/$ – see front matter Ó 2014 Elsevier Inc. All rights reserved.
chestmed.theclinics.com
Sleep disturbances in pregnancy have been well recognized since Hippocrates. In 2000, the American Academy of Sleep Medicine officially recognized sleep disorders associated with pregnancy as a separate entity defined as the occurrence of insomnia or excessive daytime sleepiness in the course of pregnancy.1 The past decade has witnessed the emergence of numerous publications on various sleep disorders associated with pregnancy. Pregnancy is a unique, short-lived state that is associated with profound physiologic changes that may predispose individuals to the development of sleep disturbances; these changes also may exacerbate preexisting conditions. Many pregnancy-related factors may result in sleep disruption.2 Heartburn is significantly more common in pregnancy and has been reported in up to 75% of pregnancies in one study.3 Oxytocin, the hormone that is responsible for uterine contractions, is known to peak at night, possibly
2
Oyiengo et al consideration the effect of the untreated conditions on the health of the pregnancy and the fetus. This review focuses on nonbreathing-related sleep disorders, with a brief mention of sleep-disordered breathing. A detailed discussion of physiologic changes of pregnancy resulting in sleep disruption is outside the scope of this article.
In summary, sleep-disordered breathing is prevalent in pregnancy and is associated with adverse outcomes. Optimal management of pregnant women with obstructive sleep apnea is unclear and should follow nonpregnant guidelines until evidence suggesting that CPAP modifies pregnancyspecific outcomes exists.
SLEEP-DISORDERED BREATHING
RESTLESS LEGS SYNDROME
Many of the physiologic changes of pregnancy predispose to sleep-disordered breathing. Upper airway edema,5 increased Mallampati score,6 nasal congestion,7 and reduction in functional residual capacity8 are all predisposing factors, as they contribute to decreased airway patency and increased collapsibility. Despite protective factors, the balance tips toward a higher incidence of sleep-disordered breathing in this population compared with the nonpregnant population. Sleep-disordered breathing has been repeatedly associated with negative pregnancy outcomes, such as gestational hypertensive disorders,9,10 gestational diabetes,9,11–14 and cesarean deliveries.9,10 Adverse fetal outcomes also have been described, but are less consistent. Growth restriction has been described in some studies,15,16 but not others.9,17–20 Preterm birth has been described in women who snore or have obstructive sleep apnea,9,10 but this complication is likely mediated by preeclampsia. Fetal heart rate decelerations were described in clinical studies21,22; however, recent polysomnographic data do not show decelerations following apneic episodes.23 One recent retrospective study has shown that the risk of a composite set of adverse outcomes increases with the severity of sleep-disordered breathing.24 These data suggest that, like the nonpregnant population, pregnant women with more severe disease need to be offered treatment. It remains unclear, however, whether continuous positive airway pressure (CPAP) alters pregnancy outcomes. Small studies and case series of women with obstructive sleep apnea25,26 show an improvement in daytime somnolence, quality of life, and other symptoms, such as morning headaches. However, the impact of CPAP on the prevention of gestational hypertension, gestational diabetes, or fetal outcomes in the setting of obstructive sleep apnea remains unclear. Minimal data have assessed sleep-disordered breathing outside the setting of obstructive sleep apnea and snoring. Central sleep apnea appears to be quite uncommon in pregnant women with sleep-disordered breathing.27 Treatment of these conditions is usually extrapolated from the nonpregnant population.
Restless legs syndrome (RLS), now known as Willis Ekbom disease (WED), is a sensorimotor phenomenon characterized by an urge to move the legs because of an unpleasant sensation; the urge is worse during periods of rest or inactivity and is partially or totally relieved by movement, and the sensation is worse during the evening or at night. Although a sleep study is not required to make the diagnosis of RLS/WED, the vast majority of patients with RLS/WED have evidence of periodic limb movements and arousals on polysomnography.28 Depending on methodology in communitybased surveys in the nonpregnant population, RLS/WED estimates fall between 1.9% and 15.0%29 and appear to have a female predominance.30 RLS/WED has a higher prevalence in pregnancy, with more than a quarter of pregnant women reported to have the syndrome in some studies.31,32 However, the methodology and the gestational age at the time of administration of questionnaires in these epidemiologic studies varied significantly. Although some used selfadministered questionnaires,33,34 others used interview-based information.35–37 Timing of data collection also varied significantly, with some studies performing the assessment longitudinally throughout pregnancy,38,39 while others performed a cross-sectional analysis at various points during pregnancy.31,40 Importantly, the number of criteria met for the diagnosis of RLS also differed between studies. In a study that performed face-to-face interviews with pregnant women conducted at delivery, nearly a quarter of pregnant women met criteria for RLS according to the International Restless Legs Syndrome Study Group criteria.35 Almost two-thirds of these women had newonset symptoms, whereas about one-third had symptoms predating pregnancy. The prevalence of RLS appears to increase with gestational age,33,38,39 suggesting de novo symptoms. For most women, symptoms resolve shortly after delivery.36,40 Lower prevalence was reported in other studies33 and the discrepancy may be related to methodology and the diagnostic criteria used.
Sleep Disorders in Pregnancy Pathophysiology RLS has been linked to dopamine metabolism in the brain, and it is thought that the disorder arises from dysfunction of hypothalamic dopaminergic cells that are the source of spinal dopamine. By impeding the production of tyrosine hydroxylase in the central nervous system, reduced serum iron hinders the production of dopamine. A potential mechanism for the higher prevalence of RLS in pregnancy may be the threefold to fourfold increase in iron requirements in pregnancy.32 As the mother is the sole source of nutrients to the fetus, the placenta upregulates its iron transfer systems to maintain adequate supply to the fetus, which often occurs at the expense of the mother’s stores.41 This upregulation is more pronounced under conditions of maternal iron deficiency.42 As many as 30% of women have limited iron stores in wealthy cities in developed countries43 and up to 90% of pregnant American women have suboptimal iron intake.44 Serum iron follows a circadian pattern and levels are 50% to 60% lower at night than in the daytime, and nadir levels appear to correlate with the highest severity of symptoms. Although serum iron and iron saturation are decreased in 62% and 77% of patients with RLS, respectively, serum ferritin levels and markers of anemia based on hemoglobin and red blood cell mass were decreased in fewer than a quarter of patients in one study.45 Ferritin levels less than 50 ng/ mL correlate well with poor sleep quality and higher symptom severity scores.46 As attractive as this theory of iron deficiency is in explaining the higher prevalence of RLS in pregnancy, it does not explain the rapid improvement that occurs postpartum, as blood loss at delivery and fluid shifts postpartum would likely worsen anemia. Furthermore, folate deficiency also may play a role in the pathogenesis of RLS in pregnancy. Folate requirements increase 8-fold to 10-fold in pregnancy because of the increased demands of the fetus. The incidence of RLS is significantly lower in women who use vitamin supplementation throughout pregnancy compared with those who do not,37,47 and resolution of symptoms correlates with normalization of levels.48 Female hormones may be culprits as well. Through interactions with the dopaminergic system, namely the nigrostriatal dopaminergic neurons, estradiol may play a role in RLS.49 In a small study of 10 pregnant women with RLS and pregnant controls without RLS, estradiol levels were significantly higher in women with RLS, irrespective of whether RLS predated the pregnancy or occurred de novo in pregnancy.50 A more recent study that excluded pregnant women being
treated with intravenous iron for iron deficiency, reported a lower prevalence of the disorder than previously described (12%) and showed similar levels of third-trimester estradiol levels in pregnant women with RLS compared with controls.51 Prolactin also influences the dopaminergic system, has the same circadian rhythmicity as RLS, and may play a role in RLS in pregnancy. However, the drastic improvement in symptoms in the postpartum period, even in lactating women,52 argues against a prominent role of this hormone. Progesterone increases several-fold in pregnancy. Although progesterone increases neuronal excitability and may theoretically manifest this excitability as RLS, progesterone levels in pregnant women with RLS were not found to be higher than those without the syndrome.37,50
Management Certain conditions should be excluded before diagnosing a patient with RLS, such as electrolyte imbalance and peripheral vasculopathy, but some conditions need to be specifically considered in the pregnant population. Leg cramps are quite common in pregnancy and may mimic RLS symptoms. Musculoskeletal discomfort is common, and nerve impingement should be considered, especially if symptoms are unilateral. RLS has been linked to hypertension in some general population studies,53,54 but only one recent study has evaluated a link between RLS and pregnancy outcomes.55 Until this association is confirmed in additional studies, it is premature to think that treatment of RLS could modify any pregnancy outcomes. Similar to nonpregnant patients, known triggers to RLS, such as caffeine, smoking, and certain drugs, should be eliminated if possible. RLS has been described in association with the use of some antidepressants in some studies56–58 but not in others.59,60 As untreated mood disorders are associated with adverse pregnancy outcomes, the safety of withholding or switching antidepressants should be carefully assessed, preferably by a perinatal psychiatrist, and the risk and benefit of such a decision carefully weighed. In 2012, American Academy of Sleep Medicine practice parameters summarized available options for the treatment of RLS in the general population and in some special populations, but provided no recommendations for the pregnant population.61 Although moderate and high-quality evidence supports the use of some drugs in the treatment of RLS, first-line therapy varies in pregnancy because of the scarcity of safety data in this population. Table 1 summarizes the safety
3
4
Table 1 Pharmacotherapy and drug safety in restless legs syndrome
Pramipexole (Approved for indication)
Ropinirole (Approved for indication)
Levodopa (Approved, but off-label use)
Opioids (Approved, but off-label use)
Gabapentin (Approved for indication)
Carbamazepine (Approved, but off-label use)
Pregnancy Safety
Lactation
Based on studies in rats and rabbits, an increase in malformations is not anticipated in women treated with pramipexole during pregnancy.62 Human safety data are limited to case reports and case series but do not show evidence of malformations. There are no human data. Based on experimental animal studies, ropinirole is not expected to increase the risk of congenital anomalies. One case report has been identified on use of Ropinirole in pregnancy.135 Levodopa produces adverse pregnancy and fetal outcomes136–138 in experimental animals after high-dose treatment. Case reports in humans have not identified abnormal embryo or fetal development. Theoretic concern about placental perfusion with levodopa.139 Current data do not support the safety of this drug in pregnancy. Neonatal withdrawal after maternal use has occurred with opioid medications. Oxycodone use in the first trimester was associated with an increase in pulmonary valve stenosis in one retrospective study.140 Study limited by maternal recall and findings confounded by indication for use. These findings were not confirmed in other studies.141–143 Gabapentin has been reported to interfere with embryo development in some but not all experimental studies. There are case reports of normal pregnancy outcomes after gabapentin therapy, but there are also reports of malformations. It is not known if the risk of malformations in increased with this medication. Carbamazepine use during early pregnancy has been associated with an increased risk of neural tube defects and possibly an increased risk of craniofacial abnormalities and developmental delay. In spite of these risks, this drug has been used for optimal seizure control as benefit likely outweighs the risk in most cases. However, until RLS is clearly linked to adverse pregnancy outcomes, the use of carbamazepine for the treatment of RLS may not outweigh the risk of fetal malformations.
No human studies assessing levels in breast milk are available. Pramipexole is known to reduce the secretion of prolactin, and it is possible that it could significantly reduce milk synthesis in breastfeeding mothers. This product should probably not be used in breastfeeding mothers.63 No human studies are available concerning levels in milk. Medication might inhibit lactation because of its prolactinlowering effects. This product should probably not be used in breastfeeding mothers.63 No pediatric concerns reported. However, reduced prolactin levels by dopamine may reduce milk production.63
Small amounts are secreted in breast milk. Sedation of the newborn may be observed.63
Data reveal that the infant plasma levels following exposure to gabapentin through breastfeeding are probably too low to cause untoward effects in the breastfed infant. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding. The amount of carbamazepine transferred to the infant is apparently quite low. Medication usually compatible with breastfeeding according to the American Academy of Pediatrics (AAP) and World Health Organization (WHO).
Oyiengo et al
Medications Restless Leg Syndrome (RLS)
Clonidine (Approved, but off-label use)
Pregabalin (Approved, but off-label use)
Rotigotine (Withdrawn from US market because of drug crystallization affecting absorption) Bromocriptine
Cabergoline
Clonazepam
Magnitude of potential teratogenic effect is undetermined. No animal teratology studies have been published.
Based on experimental animal studies and limited human experience, bromocriptine use during pregnancy is not believed to increase the risk of congenital anomalies. Risk and benefit of the use of this drug should be carefully weighed in women with RLS. Human studies of more than 500 pregnancies exposed to cabergoline suggest that the drug does not increase the risk of congenital malformations. Cabergoline has been used to increase fertility in women with prolactinomas. Maternal use of valproic acid alone or in combination with other antiepileptic drugs has been found to cause valproic acid syndrome in infants. Facial dysmorphology, congenital heart defects, spina bifida, cleft lip and palate, and developmental delays are some of the teratogenic effects seen. The use of this drug for the treatment of RLS in pregnancy cannot be justified. Maternal use is not thought to increase the risk of congenital malformations. Risk of transient respiratory distress and hypotonia in women taking clonazepam in combination with paroxetine.
Clonidine is minimally excreted in human milk. No pediatric concerns reported, but newborns may need to be observed for hypotension. Clonidine may reduce milk production by reducing prolactin secretion.
There are no data available on the transfer of pregabalin into human milk. However, due to the kinetics of the drug, its passage into the milk compartment is probable, and its oral bioavailability to the infant would be high. Therefore, infant risk cannot be ruled out. No data are available on the transfer of rotigotine into human milk. It is possible that this medication could significantly decrease prolactin release and in turn, decrease milk production. No reports of direct toxicity to infant via milk, but use with caution. May inhibit lactation.
Drug used to treat prolactinomas and is known to decrease prolactin levels. If lactation can be maintained, watch infant for ergot effects, if any. No adverse events have been associated with breastfeeding. Maternal medication usually compatible with breastfeeding according to the AAP and WHO. Monitor infant for side effects.
One case report of apnea, cyanosis, and hypotonia in a newborn exposed to clonazepam via breast milk.145 Other reports (11 newborns) showed no side effects.146
Sleep Disorders in Pregnancy
Valproic acid
Based on experimental animal studies, clonidine use during pregnancy is not expected to increase the risk of structural malformations. Possible behavioral effects, such as hyperactivity and sleep disturbances, were reported in children exposed prenatally compared with a control population.144 Similar behavioral effects of prenatal clonidine exposure have been reported in experimental animals. Pregabalin has adverse effects on embryo development and viability in rats at plasma levels about twice those achieved in humans on therapy. Human data are limited.
5
6
Oyiengo et al data available both in pregnancy and lactation. Reprotox.org and Thomas Hale’s Medications and Mothers’ Milk62,63 are excellent sources of updated information on drug safety during pregnancy and lactation. Briefly, iron supplementation starting at ferritin less than 50 ng/mL or hemoglobin less than 11 g/dL may result in symptomatic improvement in women with low iron stores or iron deficiency. Preliminary data describing the use of intravenous iron supplementation appear to be promising. Data published in an abstract form on 11 women with moderate to severe iron deficiency–associated RLS and treated with intravenous iron in the third trimester showed a significant improvement in RLS severity score from 25 5 to 7 6, P 5 .01, 4 weeks after administration.64 The effect of the mild reduction in blood pressure associated with iron infusion on placental perfusion remains unclear and more data are needed to assess the exact role of this therapy in pregnancy. Although case reports of intravenous magnesium were associated with significant improvement in RLS symptom score, the Food and Drug Administration recently issued a warning against the use of intravenous magnesium for more than 5 to 7 days because of the effect of this mineral on calcium metabolism and fetal bone development. In addition to oral or intravenous iron supplementation in women with iron deficiency, clonidine, opioids, and clonazepam are potential therapeutic options in pregnancy, although none is standard therapy based on the recent practice parameters classification.61 Newborns exposed to opioids in utero should be observed closely for respiratory depression, or the drugs discontinued close to term. Although bromocriptine and cabergoline have been used to improve fertility and in pregnancy in women with prolactinomas, the risk-benefit ratio of the use of these drugs in RLS in pregnancy is less clear. In our opinion, these medications should be reserved for more severe cases in which symptoms are significantly disrupting sleep and are not responding to other therapy. In summary, RLS/WED is a common disorder in pregnancy that adversely affects sleep. Iron, folate, and hormones may each play a role in the pathogenesis of this disorder; however, the exact mechanism underlying this higher prevalence is unclear. Drugs with lower quality of evidence in the nonpregnant population than first-line therapy may be options for therapy in pregnancy.
INSOMNIA The National Sleep Foundation recommends 7 to 9 hours of sleep per 24 hours for adults65; however,
sleep needs and duration vary by age and gender and are likely different in pregnancy. Although selfreported sleep duration does not correlate well with subjective measurements, such as actigraphy, in pregnancy,66,67 most epidemiologic studies evaluating sleep duration rely on self-reports.68,69 Based on these studies, it appears that sleep duration increases starting in the first trimester and is then reduced late in pregnancy.70–72 These reports suggest that sleep needs are likely increased in pregnancy, or that longer sleep duration is related to rising levels of hormones necessary for maintaining pregnancy, such as human chorionic gonadotropin and progesterone.2 However, the emerging literature suggesting an association of sleep deficiency with some adverse outcomes in pregnancy may indicate that the longer sleep duration may be a necessary phenomenon rather than a mere side effect of hormonal changes. Sleep disruption is a common occurrence in pregnancy, and in many cases, sleep fragmentation may be related to physiologic changes of pregnancy. Many factors, such as musculoskeletal discomfort, heartburn, nocturia, uterine contractions, and fetal movement, may all disrupt sleep.2,73 Disrupted sleep is more prevalent in the third trimester and more than half of women report poor sleep in the last 8 weeks of gestation.74 As a result of fragmented nocturnal sleep, daytime napping increases in late pregnancy. Factors that have been associated with shorter sleep duration75 and worse insomnia severity scores in pregnancy76 include nulliparity, younger age,75 smoking, advanced gestational age, and higher blood pressure.76 Postpartum sleep is usually disrupted by the newborn’s nocturnal needs and potential postpartum discomfort, with more frequent complaints of insomnia in women with operative deliveries.77 Higher Epworth Sleepiness Scale (ESS) scores also have been described in pregnancy, with up to 24% of women reporting excessive sleepiness.76,78,79 Although daytime sleepiness may relate to physiologic sleep disruption, ESS scores appear to correlate with sleep-disordered breathing80 and may add to the risk of some adverse pregnancy outcomes related to snoring.8
Sleep Deficiency and Pregnancy Outcomes Although poor sleep in the antepartum period is related to normal physiologic changes of pregnancy in many, differentiating between normal and abnormal sleep in pregnancy may be challenging but an important task nonetheless, as poor sleep has been linked to adverse pregnancy outcomes. Sleep disruption or deficiency during
Sleep Disorders in Pregnancy pregnancy is considered a significant risk factor for the occurrence of mood disturbances,81–85 as well as the recurrence of depression.86 More so, a recent placebo-controlled randomized clinical trial with diphenhydramine, trazodone, or placebo has shown a significant improvement in the sleep profile of women treated with any of the active drugs during pregnancy compared with placebo, and a significant reduction in depressive symptoms 2 and 6 weeks after delivery.87 Another pilot open intervention tested the effect of cognitive behavioral therapy for insomnia on mood, sleep, and fatigue in women with depression and insomnia.88 This study has shown significant improvement in sleep efficiency and total wake time on sleep diary, in addition to significant enhancement of subjective mood and insomnia severity, sleep quality, and fatigue. These studies do suggest that there may be a causal link between sleep duration and quality and insomnia in peripartum women. Other outcomes that have been linked to short sleep duration include labor duration and delivery mode. In a study by Lee and Gay,89 the investigators showed that short sleep duration (less than 6 hours) in the last month of pregnancy was associated with longer labor duration and a higher risk of cesarean deliveries in nulliparous women. Similar studies have demonstrated the association of nocturnal and diurnal total sleep time with these outcomes.75,90,91 It is possible that abnormal sleep may lead to fatigue, which may then predispose to longer labor. However, factors that may lead to both poor sleep and longer labor, such as emotional stressors, also may explain these findings but have not yet been elucidated. Preterm birth, defined as birth occurring before 37 completed weeks of gestation, is a major health burden and a source of significant infant morbidity. Studies from more than 2 decades ago suggested a connection between sleep disruption and preterm labor. Nearly half of women residents who spent at least 1 night a week without any sleep or worked long hours were more likely to experience preterm labor than male residents’ partners.92,93 More recently, poor sleep quality measured by the Pittsburgh Sleep Quality Index (PSQI) was shown to be associated with preterm birth.94 Despite of these findings, little has been done to investigate the link between sleep deprivation and preterm labor. It is possible that inflammation and hypothalamic pituitary axis (HPA) dysfunction, which are believed to be potential underlying mechanisms for preterm labor, are negatively influenced by poor sleep. Sleep disturbances measured by the PSQI and sleep diaries were shown to be associated with increased levels
of interleukin 695 and C-reactive protein96 in pregnancy. As sleep, mood disturbances, and stress may be associated with HPA dysfunction, which has been linked to preterm birth, preliminary data are evaluating the interactions among these disturbances.97
Treatment Cognitive behavioral therapy (CBT) is recommended for the treatment of insomnia in the nonpregnant population. Data on the use of CBT in pregnancy are lacking. One recent study has reported an improvement in sleep measures and mood in women with insomnia and depression who were treated with CBT for insomnia.88 Because of fears of teratogenicity, many drugs are avoided in pregnancy. A recent study98 showed no increase in the risk of congenital anomalies in women treated with nonbenzodiazepines zaleplon (n 5 32), zolpidem (n 5 603), and zopiclone (n 5 692). Table 2 summarizes the safety data of drugs commonly used for the treatment of insomnia. In summary, sleep disruption is common in pregnancy and may be due to physiologic factors. As poor sleep has been associated with adverse pregnancy outcomes, testing whether interventions to improve sleep quality would have a positive effect on pregnancy outcomes is needed.
NARCOLEPSY Narcolepsy is an uncommon clinical syndrome of daytime sleepiness and may be accompanied by cataplexy, hypnagogic hallucinations, and sleep paralysis. Narcolepsy can occur with or without cataplexy. According to the US population estimates, it afflicts approximately 1 in 3000 individuals.99 As narcolepsy peaks in the adolescent years to early 20s, it is likely that women who carry the diagnosis will have a pregnancy complicated by the disorder.
Pathophysiology The symptoms of narcolepsy largely reflect a dysregulation of the transition between wakefulness, non–rapid eye movement (REM), and REM sleep.100–102 The normal sleep-wake cycle is regulated by a complex interaction of neurohormones and chemicals. Hypocretin 1 and 2 (Orexin A and B) are neuropeptides synthesized in the lateral hypothalamus and are implicated in the pathogenesis of narcolepsy.103,104 Hypocretins/orexins, peptides produced by the lateral hypothalamus, orchestrate the interaction of the monoaminergic and cholinergic systems in the regulation of sleep
7
8
Pregnancy Safety
Lactation
Zaleplon
Study of 32 pregnant women suggests no increased risk of teratogenicity; however, numbers too small to be conclusive.98
Zolpidem
Study of 603 pregnancies with zolpidem exposure showed no increased risk of congenital anomalies.98 However, population-based study in Taiwan (n 5 2497 exposed women and 12,485 unexposed) showed an increased risk of low birth weight and preterm deliveries in women but no increased risk of congenital anomalies.148 Study of 692 pregnancies showed no increased risk of malformations.98 Other smaller studies showed similar results.151,152 Crosses placental barrier and withdrawal reported at birth.153 Animal studies suggest dose-dependent incidence of diaphragmatic hernia and scapular shape abnormalities.154 Human data are lacking. Large-scale studies and case-control data fail to show an association with congenital malformations.155,156 Not likely to result in major congenital malformations based on human reports.157–159 Based on animal and human reports, the drug is not expected to increase the risk of congenital malformations but human reports are scarce. Based on animal and human studies, the drug is not expected to increase the risk of congenital malformations.162 There is some suggestion in the literature that first-trimester use may be associated with various (rather than a single) anomalies.163,164 Early data on diazepam and chlordiazepoxide use in first trimester suggesting increased risk of cleft palate were not supported by later studies. Concern about neonatal withdrawal with late third-trimester use. Concomitant use with diphenhydramine has been associated with fetal death.165
Estimated infant dose
